My Market Wizard

Oric Pharmaceuticals, Inc. 8-K Analysis & Summary – 3/14/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

Oric Pharmaceuticals, Inc.
,

Filing date:

03/14/2025

TLDR:

Oric Pharmaceuticals, Inc. amended and restated its 2022 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance.

ELI5:

Oric Pharma is giving itself more flexibility to offer stock as a way to attract new employees and handle mergers or acquisitions. They’ve increased the number of shares they can use for this purpose.

Accession #:

0001193125-25-054784

Published on

Analyst Summary

  • The Compensation Committee of Oric Pharmaceuticals approved an amendment to the 2022 Inducement Equity Incentive Plan.
  • The amendment increases the number of shares reserved for issuance under the plan by 1,100,000, bringing the total to 2,250,000 shares.
  • The Inducement Plan allows for the grant of equity-based awards, including stock options, restricted stock units, and performance shares.
  • Awards can only be made to individuals not previously employees or non-employee directors, as an inducement to employment, or in connection with a merger or acquisition, in accordance with Nasdaq Listing Rules.
  • The terms of the Inducement Plan are substantially similar to the Company’s 2020 Equity Incentive Plan, including treatment of equity awards in the event of a merger or change in control.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️